REBEKAH NASSERI: Open Payments
NPI 1073278925 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,033 in 85 payments from 15 companies in 2025. Trend: 2023 $1,686 · 2024 $2,348 · 2025 $2,033
Food & beverage: $2,033
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 16 | $302 |
| Novartis Pharmaceuticals Corporation | 25 | $248 |
| Amgen Inc. | 6 | $235 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $234 |
| Alnylam Pharmaceuticals Inc. | 9 | $215 |
| HEARTFLOW, INC. | 3 | $174 |
| ABIOMED | 1 | $150 |
| BIOTRONIK INC. | 1 | $126 |
| SCPHARMACEUTICALS INC. | 4 | $92 |
| PFIZER INC. | 4 | $74 |
Products named: CAMZYOS, LEQVIO, REPATHA, Kerendia, FFRct, ONPATTRO, Rivacor 7 DR-T, FUROSCIX.
Industry payments across TX — which companies pay providers there.
